Evidence map›Paper›PMID 41257272›Full record

ArticleWorld journal of gastroenterology2025

Pescadillo ribosomal biogenesis factor 1 as a therapeutic target in tumor immunotherapy.

Jia Yu, Bo Yu, Fei-Lin Ge, Zhi-Gang Ren

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jia YuDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Bo YuDepartment of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Fei-Lin GeDepartment of Chinese Medicine, State Key Laboratory of Antiviral Drugs, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China.
Zhi-Gang RenDepartment of Infectious Diseases, State Key Laboratory of Antiviral Drugs, Pingyuan Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. fccrenzg@zzu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High expression of pescadillo ribosomal biogenesis factor 1 (PES1) has been reported across multiple cancer types and is significantly associated with poor prognosis. Hu

Indexed as

ImmunotherapyRNA-Binding ProteinsStomach NeoplasmsB7-H1 AntigenBiomarkers, TumorCD8-Positive T-LymphocytesGene Expression Regulation, NeoplasticHumansImmune Checkpoint InhibitorsLymphocytes, Tumor-InfiltratingPrognosisSignal TransductionTumor EscapeTumor MicroenvironmentB7-H1 AntigenBiomarkers, TumorCD274 protein, humanImmune Checkpoint InhibitorsRNA-Binding ProteinsImmune evasion mechanismsPescadillo ribosomal biogenesis factor 1Programmed death-ligand 1Tumor immune evasionTumor immunotherapy

Identifiers

PMID41257272
PMCPMC12620791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.